伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例

doi:10.3969/j.issn.1009-976X.2021.06.018

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (06): 675-678.DOI: 10.3969/j.issn.1009-976X.2021.06.018

伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例

桂秀娟, 赵健丽, 汪颖, 柴洁, 丁林潇潇, 姚和瑞^*

中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120

通讯作者: * 姚和瑞,Email：yaoherui@mail.sysu.edu.cn
基金资助:
国家自然科学基金（82071754）

The successful application of inetetamab combined with pyrotinib in the treatment of HER-2 positive advanced breast cancer： a case report

GUI Xiu-juan, ZHAO Jian-li, WANG Ying, CHAI Jie, DIN Lin-xiao-xiao, YAO He-rui

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Received:2021-10-08 Online:2021-12-20 Published:2022-01-19
Contact: YAO He-rui, yaoherui@mail.sysu.edu.cn

摘要/Abstract

摘要： HER2阳性乳腺癌约占所有乳腺癌的15%~20%,其侵袭性强且预后较差。曲妥珠单抗的应用显著改善了患者的预后,但仍有部分患者会出现曲妥珠单抗耐药。本文报道一例应用“伊尼妥单抗”联合“吡咯替尼”及“艾立布林”后疗效显著的曲妥珠单抗原发耐药的晚期乳腺癌患者。

关键词: 伊尼妥单抗, 吡咯替尼, 曲妥珠单抗耐药, HER2阳性乳腺癌

Abstract: Approximately 15%~20% of patients with metastatic breast cancer have HER2-positive disease, which isassociated with more aggressive disease biology and historically, a poorer prognosis relative to other molecular subtypes. The application of trastuzumab has greatly improved patients outcomes,however, trastuzumab-resistance is common. We presented a HER-2 positive metastatic breast cancer case, who was diagnosed as primary trastuzumab resistance and successfully treated with inetetamab combined with pyrotinib and eribulin.

Key words: inetetamab, pyrotinib, trastuzumab-resistance, HER2 positive breast cancer

中图分类号:

R739.7

桂秀娟, 赵健丽, 汪颖, 柴洁, 丁林潇潇, 姚和瑞. 伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例[J]. 岭南现代临床外科, 2021, 21(06): 675-678.

GUI Xiu-juan, ZHAO Jian-li, WANG Ying, CHAI Jie, DIN Lin-xiao-xiao, YAO He-rui. The successful application of inetetamab combined with pyrotinib in the treatment of HER-2 positive advanced breast cancer： a case report[J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 675-678.

参考文献

[1] Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Fan L,Strasser-Weippl K,Li JJ,et al.Goss PE: Breast cancer in China[J]. Lancet Oncol, 2014,15(7):e279-289.
[3] Chen X,Wang J,Fan Y,et al.Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice[J]. Clin Breast Cancer,2021, 21(3):191-198.
[4] Wong H,Leung R,Kwong A,et al.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 metastatic breast cancer[J]. Oncologist, 2011, 16(11):1535-1546.
[5] Verma S,Miles D,Gianni L,et al.Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer[J]. N Engl J Med,2012, 367(19):1783-1791.
[6] Xu B,Yan M,Ma F,et al.Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021,22(3):351-360.
[7] Moore GL,Chen H,Karki S,et al.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions[J]. MAbs, 2010,2(2):181-189.
[8] Rugo H,Im SA,Cardoso F,et al.Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2021,7(4):573-584.
[9] 边莉,徐兵河,邸立军,等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30):2351-2357.
[10] Shiraishi K, Mimura K,Izawa S,et al.Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity[J]. Gastric Cancer, 2013, 16(4):571-580.
[11] Okita R,Shimizu K,Nojima Y,et al.Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells[J]. Oncol Rep, 2015, 34(6):2864-2870.
[12] Mimura K,Kamiya T,Shiraishi K,et al.Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer[J]. Int J Cancer, 2014, 135(6):1390-1398.

伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例

The successful application of inetetamab combined with pyrotinib in the treatment of HER-2 positive advanced breast cancer： a case report

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics